Latanoprostene bunod - Bausch & Lomb/NicOx

Drug Profile

Latanoprostene bunod - Bausch & Lomb/NicOx

Alternative Names: BOL-303259-X; NCX-116; PF-03187207; PF-3187207; Vesneo; Vyzulta

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NicOx
  • Developer Bausch & Lomb
  • Class Antiglaucomas; Nitro compounds; Prostaglandins; Small molecules
  • Mechanism of Action Nitric oxide donors; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Glaucoma; Ocular hypertension

Most Recent Events

  • 11 Dec 2017 Latanoprostene bunod is not yet available for Glaucoma and Ocular hypertension in USA (Ophthalmic,Drops) (literature review)
  • 02 Nov 2017 Bausch & Lomb intends to launch latanoprostene bunod for Glaucoma, Ocular hypertension in USA (Ophthalmic,drops) before the end of 2017
  • 02 Nov 2017 Registered for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top